NCT05175053

Brief Summary

Acute kidney injury (AKI) is one of the major complications after cardiac surgery that may affects 20% to 40% of patients according to the definitions. Also, AKI after cardiac surgery is associated with high morbidity and mortality, with eight-fold increase in the odds ratio of death when renal replacement therapy (RRT) is required. However the indication and the optimal timing of RRT initiation are still controversial. We hypothesized that a strategy of early initiation of RRT would result in a lower risk of surgical mortality than a standard strategy in post cardiac surgery patients with AKI of Kidney Disease: Improving Global Outcomes (KDIGO) classification stage 2 (serum creatinine, 2.0 times the baseline level; urine output, \<0.5mL/kg/h for 6 or more hours).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 10, 2021

Completed
14 days until next milestone

Study Start

First participant enrolled

December 24, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 3, 2022

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 11, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 11, 2026

Completed
Last Updated

February 12, 2026

Status Verified

February 1, 2026

Enrollment Period

4.1 years

First QC Date

December 10, 2021

Last Update Submit

February 10, 2026

Conditions

Keywords

Acute Kidney InjuryPost Cardiac SurgeryRenal Replacement Therapy

Outcome Measures

Primary Outcomes (1)

  • Number of participants with operative mortality

    any death, regardless of cause, occurring (1) within 30 days after surgery in or out of the hospital, and (2) after 30 days during the same hospitalization subsequent to the operation

    at postoperative 30 days

Secondary Outcomes (8)

  • Overall survival

    at postoperative 90 days

  • Number of participants with cardiovascular mortality

    at postoperative 90 days

  • Number of participants with renal replacement therapy dependency

    at postoperative 90 days

  • Number of participants with major adverse kidney events (MAKE)

    at postoperative 90 days

  • Number of participants with renal replacement therapy related morbidity

    at postoperative 90 days

  • +3 more secondary outcomes

Study Arms (2)

Early RRT group

EXPERIMENTAL

Patients who will undergo renal replacement therapy (RRT) within 6 hours of diagnosis of stage 2 acute kidney injury (AKI).

Other: Renal replacement therapy

Delayed RRT group

ACTIVE COMPARATOR

Patients who will undergo renal replacement therapy (RRT) if one of the absolute indications for RRT is present.

Other: Best medical management

Interventions

The best medical management continues until the patient meets absolute indication of renal replacement therapy

Delayed RRT group

Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)

Early RRT group

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients within 7 days after cardiac surgery
  • Acute kidney injury (AKI) described as Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 (urine output \<0.5mL/kg/h for ≥6h or 2-fold increase in serum creatinine compared with baseline)

You may not qualify if:

  • previous renal replacement therapy
  • AKI secondary to obstructive nephropathy
  • previous kidney transplantation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Seoul National University Bundang Hospital

Seongnam, South Korea

Location

Seoul National University Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Acute Kidney Injury

Interventions

Renal Replacement Therapy

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Ho Young Hwang, MD, PhD

    Seoul National University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 10, 2021

First Posted

January 3, 2022

Study Start

December 24, 2021

Primary Completion

February 11, 2026

Study Completion

February 11, 2026

Last Updated

February 12, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

IPD will not be shared because it is not allowed by our institutional IRB.

Locations